A New Way of Treating the Flu

Jun 13, 2009
Linhardt’s new compound (green spheres) blocks both the N (pink spikes) and H (blue spikes) portion of the flu virus. The compound prevents the infection of the cell and the spread of the flu to other cells like no other compound before. Photo Credit: Rensselaer/Melissa Kemp.

What happens if the next big influenza mutation proves resistant to the available anti-viral drugs? This question is presenting itself right now to scientists and health officials this week at the World Health Assembly in Geneva, Switzerland, as they continue to do battle with H1N1, the so-called swine flu, and prepare for the next iteration of the ever-changing flu virus.

Promising new research announced by Rensselaer Polytechnic Institute could provide an entirely new tool to combat the flu. The discovery is a one-two punch against the illness that targets the illness on two fronts, going one critical step further than any currently available flu .

“We have been fortunate with H1N1 because it has been responding well to available drugs. But if the virus mutates substantially, the currently available drugs might be ineffective because they only target one portion of the virus,” said Robert Linhardt, the Ann and John H. Broadbent Jr. ’59 Senior Constellation Professor of Biocatalysis and Metabolic Engineering at Rensselaer. “By targeting both portions of the virus, the H and the N, we can interfere with both the initial attachment to the cell that is being infected and the release of the budding virus from the cell that has been affected.”

The findings of the team, which have broad implications for future flu drugs, will be featured on the cover of the June edition of European Journal of Organic Chemistry.

The influenza A virus is classified based on the form of two of its outer proteins, hemagglutinin (H) and neuraminidase (N). Each classification — for example H5NI “” or H1N1 “” — represents a different mutation of hemagglutinin and neuraminidase or H and N.

Flu drugs currently on the market target only the neuraminidase proteins, and disrupt the ability of the virus to escape an infected cell and move elsewhere to infect other healthy cells. The new process developed by Linhardt is already showing strong binding potential to hemagglutinin, which binds to sialic acid on the surface of a healthy cell, allowing the virus to enter the cell.

“We are seeing promising preliminary results that the chemistry of this approach will be effective in blocking the hemagglutinin portion of the disease that is currently not targeted by any drug on the market,” he said.

In addition, Linhardt and his team have shown their compound to be just as effective at targeting neuraminidase as the most popular drugs on the market, according to Linhardt.

The approach can also be modified to specifically target the neuraminidase or the hemagglutinin, or both, depending on the type of mutation that is present in the current version of the flu, according to Linhardt.

In the next steps of his research, Linhardt will look at how their compounds bind to hemagglutinin, and he will test the ability to block the virus first in cell cultures and then in infected animal models.

“It is still early in the process,” he said. “We are several steps away from a new drug, but this technique is allowing us to move very quickly in creating and testing these compounds.”

The technique that Linhardt used is the increasingly popular technique of “click chemistry.” Linhardt is among the first researchers in the world to utilize the technique to create new anti-viral agents. The process allows chemists to join small units of a substance together quickly to create a new, full substance.

In this case, Linhardt used the technique to quickly build a new derivative of sialic acid. Because it is chemically very similar to the sialic acid found on the surface of a cell, the virus could mistake the compound as the real sialic acid and bind to it instead of the cell, eliminating the connections to hemagglutinin and neuraminidase that are required for initial infection and spread of the infection in the body. The currently available drugs are translation-state inhibitors whose chemical structure allows them to only effectively target the neuraminidase.

Source: Rensselaer Polytechnic Institute (news : web)

Explore further: EU regulator: Morning-after pill OK for all women

add to favorites email to friend print save as pdf

Related Stories

Flu shot might also offer some protection against H5N1

Feb 13, 2007

The yearly influenza vaccine that health officials urge people to get each fall might also offer certain individuals some cross protection against the H5N1 virus, commonly known as bird flu, according to investigators at ...

Chemists track how drug changes, blocks flu virus

Feb 01, 2008

An anti-virus drug attacks influenza A by changing the motion and structure of a proton channel necessary for the virus to infect healthy cells, according to a recently published research paper by two Iowa ...

Recommended for you

EU regulator: Morning-after pill OK for all women

10 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

14 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

15 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

Jul 23, 2014

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

Sean_W
not rated yet Jun 13, 2009
"We have been fortunate with H1N1 because it has been responding well to available drugs"

I think that what we have really been fortunate about is that the virus may not be well adapted to the lower respiratory tract. Bird flu is and is very deadly but it is not adapted to the upper tract which is needed for easy transmission between humans. If Swine adapts to the lungs as well or if Avian flu adapts to the nose and throat then you would have a novel flu that can transmit easily and is often fatal. The 1918 flu may have started out as a nose and throat flu since it (and other pandemic flu viruses) had an initial mild "herald wave" followed by a more lethal wave. A flu that was adapted to both tracts might produce more deep coughing (from the lower infection) combined with the easier target of the next host's upper respiratory tract. This would provide a selective pressure that might overcome the tendency for more lethal diseases to die out by killing their host. The probability of a more lethal virus would go from random chance to being probable.
joy
not rated yet Jun 16, 2009
WHO has announced Swine flu as pandemic. I had got tamiflu on safe side from an online drug store International Drug Mart http://www.intern...art.com/